title: Aggravation by vanadium of magnesium deficiency in STZ-induced diabetic rats.
abstract: This study examined changes in the metabolism of magnesium (Mg), and related serum parameters, following treatment with vanadium (V) in streptozotocin-diabetic rats. Over a period of five weeks, four groups were examined: control, diabetic, diabetic-treated with 1 mg V/day or 3 mg V/day. The V was supplied in drinking water as bis(maltolato)oxovanadium(IV). The Mg levels were measured in food, faeces, urine, serum, muscle, kidney, liver, spleen, heart and femur. Albumin, uric acid, urea, total-cholesterol, LDL-cholesterol, triglycerides, aspartate-aminotransferase and alkaline-phosphatase were determined in serum. In the diabetic group, Mg retained and Mg content in serum and femur decreased, while levels of uric acid, urea, total-cholesterol, LDL-cholesterol, triglycerides and alkaline-phosphatase and aspartate-aminotransferase activity increased compared with control rats. In the diabetic group treated with 1 mg V/day, Mg retained, serum levels of Mg, urea and triglycerides, and alkaline-phosphatase activity remained unchanged, while levels of uric acid, total-cholesterol and LDL-cholesterol increased and the Mg content in femur and aspartate-aminotransferase activity decreased compared with the diabetic untreated group. In the diabetic rats treated with 3 mg V/day, food intake and glycaemia were normal. In this group, Mg content in serum, kidney and femur, levels of urea and aspartate-aminotransferase and alkaline-phosphatase activity decreased, whereas LDL-cholesterol increased, uric acid and total-cholesterol levels remained unchanged in comparison with untreated diabetic rats. In conclusion, although treatment with 3 mg V/day normalised the glycaemia, the hypomagnesaemia and tissue depletion of Mg seen in the diabetic rats, caused by the treatment with V, could have partially contributed to the fact that V did not normalise other serum parameters altered by the diabetes.
authors.affiliation: Biomedical Research Unit, Mexican Social Security Institute, Victoria de Durango, Mexico.
authors.forename: M C
authors.initials: MC
authors.lastname: Bermúdez-Peña
authors.forename: C
authors.initials: C
authors.lastname: López-Chaves
authors.forename: J
authors.initials: J
authors.lastname: Llopis
authors.forename: F
authors.initials: F
authors.lastname: Guerrero-Romero
authors.forename: M
authors.initials: M
authors.lastname: Montes-Bayón
authors.forename: A
authors.initials: A
authors.lastname: Sanz-Medel
authors.forename: C
authors.initials: C
authors.lastname: Sánchez-González
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications*; D008274:Magnesium / Q000097:blood; D008275:Magnesium Deficiency / Q000097:blood / Q000150:complications*; D008297:Male; D009928:Organ Specificity / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014639:Vanadium / Q000009:adverse effects* / Q000097:blood
chemical_list: D014639:Vanadium; D013311:Streptozocin; D008274:Magnesium
keywords: blood parameters; diabetes; interactions; magnesium; vanadium